

Accepted Manuscript

Title: Prevention of CMV Reactivation in Haploidentical Stem Cell Transplantation

Author: Aimee E. Hammerstrom, Lindsey R. Lombardi, Sai Ravi Pingali, Gabriela Rondon, Julianne Chen, Denái R. Milton, Roy F. Chemaly, Richard E. Champlin, Alison Gulbis, Stefan O. Ciurea

PII: S1083-8791(17)30751-6
DOI: <https://doi.org/doi:10.1016/j.bbmt.2017.09.018>
Reference: YBBMT 54810

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 12-6-2017
Accepted date: 28-9-2017

Please cite this article as: Aimee E. Hammerstrom, Lindsey R. Lombardi, Sai Ravi Pingali, Gabriela Rondon, Julianne Chen, Denái R. Milton, Roy F. Chemaly, Richard E. Champlin, Alison Gulbis, Stefan O. Ciurea, Prevention of CMV Reactivation in Haploidentical Stem Cell Transplantation, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/doi:10.1016/j.bbmt.2017.09.018>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Prevention of CMV reactivation in Haploidentical Stem Cell Transplantation

Aimee E. Hammerstrom, PharmD¹, Lindsey R. Lombardi, PharmD¹, Sai Ravi Pingali, MD², Gabriela Rondon, MD², Julianne Chen, BS², Denái R. Milton, MS³, Roy F. Chemaly, MD⁴, Richard E. Champlin, MD², Alison Gulbis, PharmD¹, Stefan O. Ciurea, MD²

The University of Texas MD Anderson Cancer Center ¹Division of Pharmacy; ²Department of Stem Cell Transplantation and Cellular Therapy; ³Department of Biostatistics; ⁴Department of Infectious Diseases, Infection Control, and Employee Health

Financial Disclosure Statement: No relevant conflict of interest to disclose.

Short title: Prevention of CMV reactivation in HaploSCT

Corresponding Author:

Name: Aimee Hammerstrom

Address: 1515 Holcombe Blvd Unit 377, Houston, TX 77030

Phone: 713-792-1060

Fax: 713-563-9952

Email Address: aehammer@mdanderson.org

Highlights:

- Prolonged time to CMV reactivation in haploidentical transplants was observed with ganciclovir administered before and valacyclovir administered after transplant
- A lower incidence of CMV reactivation and CMV disease was noted with this combined approach compared to traditional antiviral prophylaxis
- No higher toxicity or non-relapsed mortality was observed with combination therapy

ABSTRACT

Cytomegalovirus (CMV) infection can increase the morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Due to a higher degree of immunosuppression, haploidentical transplant recipients may be at an increased risk of viral infections, particularly CMV. We retrospectively analyzed 86 haploidentical HCT recipients at our institution, to determine whether a more intensified antiviral strategy would reduce the incidence of CMV reactivation compared with a traditional antiviral prophylaxis regimen. According to practice changes over time in antiviral prophylaxis

Download English Version:

<https://daneshyari.com/en/article/8430349>

Download Persian Version:

<https://daneshyari.com/article/8430349>

[Daneshyari.com](https://daneshyari.com)